NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

MTVA

MetaVia Inc

Apr 21 • 11:20AM ET

0.7300

Dollar change -0.0090
Percentage change -1.22	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF DFAS DFAT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.32	Insider Own	63.65%	Shs Outstand	8.64M	Perf Week	-49.66%
Market Cap	6.32M	Forward P/E	-	EPS next Y	-1.58	Insider Trans	0.00%	Shs Float	3.15M	Perf Month	-52.90%
Income	-27.59M	PEG	-	EPS next Q	-0.39	Inst Own	10.47%	Short Float	2.00%	Perf Quarter	-62.47%
Sales	0.00M	P/S	-	EPS this Y	54.07%	Inst Trans	-26.40%	Short Ratio	0.14	Perf Half Y	-75.34%
Book/sh	0.92	P/B	0.79	EPS next Y	3.36%	ROA	-141.35%	Short Interest	0.06M	Perf Year	-78.90%
Cash/sh	1.85	P/C	0.39	EPS next 5Y	20.22%	ROE	-224.18%	52W Range	0.65 - 5.30	Perf YTD	-64.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	67.49%	ROI	-345.37%	52W High	-86.23%	Beta	0.36
Dividend TTM	-	Quick Ratio	1.94	Sales past 5Y	0.00%	Gross Margin	-	52W Low	12.83%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	1.94	EPS Y/Y TTM	-75.88%	Oper. Margin	-	RSI (14)	28.76	Volatility	46.59% 17.64%
Employees	9	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	15.50
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	42.75%	Payout	-	Rel Volume	1.45	Prev Close	0.74
Sales Surprise	-	EPS Surprise	123.62%	Sales Q/Q	-	Earnings	Mar 20 BMO	Avg Volume	451.64K	Price	0.73
SMA20	-46.62%	SMA50	-51.02%	SMA200	-71.86%	Trades		Volume	208,095	Change	-1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-24	Initiated	H.C. Wainwright	Buy	$12

Apr-15-25 07:01AM	MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability (PR Newswire) -55.98%
Mar-20-25 07:31AM	MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jan-10-25 08:05AM	MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference (PR Newswire)
Dec-19-24 08:01AM	MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH (PR Newswire)
Dec-18-24 08:01AM	MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH (PR Newswire) -17.73%
07:00AM	Loading…
Dec-04-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire)
07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Dec-02-24 08:01AM	MetaVia to Present at the Emerging Growth Conference in December (PR Newswire)

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MTVA

MetaVia Inc

Upgrade your FINVIZ experience